Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Abcodia Restructures Leadership Team to Drive Commercialization of the ROCA® Test


News provided by

Abcodia Ltd

11 Jan, 2016, 13:00 GMT

Share this article

Share toX

Share this article

Share toX

This image opens in the lightbox
Abcodia Logo (PRNewsFoto/Abcodia)

BOSTON, Massachusetts and CAMBRIDGE, England, January 11, 2016 /PRNewswire/ --

  • Nadia Altomare appointed as Chief Executive Officer, Julie Barnes appointed as Chief Scientific Officer, and Chris Poole hired as Chief Financial Officer

The Board of Directors of Abcodia Ltd., a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer, today announced the restructuring and expansion of its senior executive team to facilitate the rapid global commercialization of the ROCA® Test for ovarian cancer and tests for the early detection of other cancers.

     (Logo: http://photos.prnewswire.com/prnh/20150512/743958 )

The ROCA Test was used as part of a multimodal ovarian cancer screening assessment in the UK Collaborative Trial for Ovarian Cancer Screening (UKCTOCS), a large prospective randomized controlled study of more than 200,000 initially cancer-free, postmenopausal women. Recent findings from the study published in The Lancet demonstrated that screening may reduce ovarian cancer mortality by an estimated 20 percent.

Nadia Altomare, currently President of Abcodia's U.S. subsidiary, has been appointed CEO. Ms. Altomare has a proven track record in developing new markets for medical services and has been responsible for the U.S. commercial launch of the ROCA Test in December, 2015. She has proven successful in single and multi-product/service environments spanning from entrepreneurial startups to established Fortune 500 companies. She will continue to be based out of Abcodia's U.S. headquarters in Boston.

Previously Ms. Altomare served as Vice President and General Manager of ThermoFisher Scientific (formerly Life Technologies), where she was the General Manager of the global human identification business. In this role, she oversaw a diverse professional team including sales, marketing, product management, R&D, technical support and validation services. Ms. Altomare also held leadership roles of increasing responsibility at PerkinElmer Inc., serving as the Vice President of North America Specialty Diagnostics and General Manager of their cytogenetic DNA testing business. Ms. Altomare was also Sr. Director of Commercial Operations at ViaCord (formerly ViaCell). In this capacity she led her commercial teams through several rounds of funding, merger, IPO, acquisition and eventual integration into PerkinElmer.

Dr. Julie Barnes, the founding CEO of Abcodia Ltd., has assumed the role of Chief Scientific Officer. In this capacity, she will be responsible for regulatory affairs, reimbursement strategy, medical affairs and governance. Additionally, she will lead the company's research & development activities, using the UKCTOCS data and biobank assets to which Abcodia has exclusive commercial access. As the founding CEO, Dr. Barnes has led Abcodia through its first five years of growth, including two successful rounds of venture financing, in-licensing and early commercialization of the ROCA Test and establishment of global

R&D collaborations leveraging the UKCTOCS biobank. Dr. Barnes will be based out of Abcodia's UK headquarters in Cambridge.

Mr. Chris Poole joined as Chief Financial Officer. Chris has more than 20 years of finance experience, working in a variety of roles within small startup organizations as well as a FTSE 250 listed company. Most recently he served as Chief Financial Officer at Zinwave, a global company advancing in-building wireless coverage, where Chris was instrumental in its recent acquisition by McWane. Prior to this, he was Finance Director at Enecsys Limited.  Mr. Poole also held the positions of VP of Finance and Head of Project Management at Ip.access Ltd. He also served as Financial Controller at UbiNetics and played a key role in the successful sale of the business in 2005 to Aeroflex Inc. and Cambridge Silicon Radio. Chris has a degree in Accounting and Finance from Nottingham Trent University and qualified as a Chartered Accountant with PricewaterhouseCoopers. He will be based out of the company's UK headquarters in Cambridge.

Ms. Altomare and Dr. Barnes will remain as members of Abcodia's Board of Directors and Mr. Poole will join the Board.

"These changes are a natural transition for Abcodia and we are confident that Nadia's proven track record of accelerating the commercial growth of life sciences companies, business acumen and leadership qualities will be immensely valuable as Abcodia continues to expand rapidly," said Andy Richards, Ph.D., Chairman of Abcodia's Board of Directors. "Under Julie's leadership as the founding CEO, the company has established a solid foundation by launching the ROCA Test and establishing a foothold in the early detection market. With international collaborations in place and Julie's ongoing leadership and commitment as global CSO, I am optimistic that Abcodia is in a solid position to advance its early detection programs beyond ovarian cancer."

Commenting on Ms. Altomare's new role, Julie Barnes noted "Having worked closely with Nadia for nearly a year, I am really pleased that she has accepted the role of CEO. I am confident that her commercial experience and leadership will take the company to the next level. Our skills are very complementary and I look forward to our continued partnership."

"I am delighted to become Abcodia's CEO at this exciting period in the company's development," said Ms. Altomare. "I look forward to collaborating with Julie and Chris, and to working with healthcare professionals, women's healthcare advocacy groups and medical societies to address the significant unmet need in the early detection of ovarian cancer. Additionally, I look forward to expanding Abcodia's pipeline of proprietary early detection tests for other cancers."

On his appointment of CFO, Mr. Poole stated: "I am excited to be joining Abcodia, a company with a great opportunity to grow and make a difference, supported by its highly experienced investors, board members and Nadia, Julie and other members of the executive leadership team."

About Abcodia 

Abcodia Ltd is a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer. The company's first product is the ROCA Test for the early detection of ovarian cancer, and it is expanding its pipeline of early detection technologies for lung, colorectal and pancreatic cancer. Abcodia's offerings are based on expertise in measuring and modelling dynamic changes over time of clinical variables including test results from serum-based markers before cancer is clinically diagnosed, and it maintains exclusive commercial access to a biobank of five million serum samples donated from more than 200,000 individuals over a 10-year period. Abcodia holds strategic collaborations with leading global organizations including Cancer Research UK, University College London and other academic and industry partners.

Abcodia is a privately held company funded through investments from Albion Ventures, Cambridge Innovation Capital, Scottish Equity Partners and UCL Business. Headquartered in Cambridge, U.K., the company has operations in Boston, Mass. and a clinical laboratory in Memphis, Tenn. For more information, visit http://www.abcodia.com/.

About the ROCA® Test 

Abcodia's first product, the ROCA Test, indicates a woman's likelihood of having ovarian cancer. The ROCA Test is intended for postmenopausal women aged between 50 and 85, or for certain women between 35 and 85 years of age who are considered to have a higher risk due to family history of ovarian or breast cancer or genetic mutations in, for example, the BRCA1 or BRCA2 genes. The ROCA test has been evaluated as part of a multimodal screening strategy in several prospective clinical trials in both the U.K. and U.S. involving more than 215,000 women over the past 15 years. The results of those studies show that the ROCA Test, when used with appropriate transvaginal ultrasound as the follow up test, has a higher performance than other currently available methods that have been evaluated prospectively in healthy women. In the clinical studies, the ROCA Test detects the majority of ovarian cancer cases before the first signs or symptoms of ovarian cancer appear.

The ROCA Test is CE marked and is currently available in the private healthcare market in the U.K. The ROCA Test became available as a service from Abcodia's testing laboratory in select U.S. markets in

December 2015 and it will become available in additional U.S. states throughout 2016. For more information, visit http://www.therocatest.co.uk or http://www.rocatest.com.

US MEDIA CONTACT:
Danielle Lewis
Lazar Partners
T: +1(212)843-0211
dlewis@lazarpartners.com

UK MEDIA CONTACT:
Rozi Morris/Gemma Howe
Instinctif Partners
T: +44(0)20-7457-2020
abcodia@instinctif.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.